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Letter to the editor
Breast cancer among human immunodeﬁciency virus
(HIV)-infected patients: the experience in Brescia, Northern
ItalyDear Editor,
Breast cancer is a non-acquired immunodeﬁciency syndrome
(AIDS) deﬁning malignancy that does not seem to increase in
incidence within the human immunodeﬁciency virus (HIV)-
infected female population. To this date, very few cases of
breast cancer in HIV-infected women have been recorded in
the literature.
In a recent issue of the Brazilian Journal of Infectious Dis-
eases, we readwith interest the article by deAndrade et al.,1 in
which nine breast cancer cases that occurred in a cohort of 860
HIV-infected women followed in Rio de Janeiro from May 1996
until September 2009 are described. They estimated an inci-
dence rate of breast cancer in this population of 133 cases per
100,000 person/years, similar to that observed in the general
female population of Brazil.
Up to June 2011, our cohort of HIV-infected patients
followed in the Clinic of Infectious Diseases and Tropical
Medicine in Brescia (Northern Italy) included 5,253 sub-
jects. Among these, 3,455 (65.77%) had regular follow-up, 777
(14.79%) died, and the remaining (n=1,021; 19.44%) were lost
to follow-up. Ten breast cancer cases have occurred between
1999 and 20092: from those, one case was interestingly iden-
tiﬁed in an HIV-infected man.
The HIV-infected women of our cohort with breast cancer
had a median age at diagnosis of 42 years (range 33-62 years).
Two patients had concomitant diagnosis of HIV-infection,
while in the others breast cancer was diagnosed later (within
four to 19 years after HIV diagnosis). Eight women referred
heterosexual intercourse as their mode of HIV exposure,
while one was an intravenous drug user. Two patients had
an AIDS-deﬁning event before cancer. At breast cancer diag-
nosis, median CD4+T-cell count was 424 cells/mm3 (range
60-2,158 cells/mm3), and three patients were receiving HAART
with an undetectable HIV viral-load. Histopathological analy-
ses showed not only inﬁltrating ductal carcinoma, but also a
case of inﬁltrating lobular carcinoma and a case ofmixed duc-
tal and lobular carcinoma. All but one were hormone receptorpositive. As the breast cancer diagnoses were performed at
earlier stages, every woman underwent surgical treatment;
adjuvant or neo-adjuvant chemotherapy was given in four
cases, and three patients also received radiation. Two deaths
have occurred, both due to breast cancer progression: these
two patients died 32 and 49 months after the breast cancer
diagnosis, respectively. All the other patients are still alive and
disease-free, with a median survival time of 77 months (range
32-94 months).
Following, we describe separately the breast cancer case
diagnosed in the 65-year-old Italian man. In May 2008, seven
years after diagnosis of HIV infection, he developed a painless
nodule near the nipple of his left breast. He was submit-
ted to mastectomy and axillary dissection: histopathological
study showed ductal carcinoma, staging was T1c/N1a/M0. At
breast cancer diagnosis, he was receiving HAART with unde-
tectable HIV viral load, and his CD4+T-cell count was 467
cells/mm3. He was later treated with local radiotherapy and,
as the tumour was hormone receptor-positive, he received
tamoxifen 20mg/daily. He is still alive without signs of breast
cancer disease or metastasis.
Breast cancer is the most common cancer and the leading
cause of female cancer death among women in Italy: between
2003 and 2005, it accounted for 24.9% of the total number of
female cancers and for 16.3% of the overall number of cancer
deaths among women. The incidence of breast cancer in Ital-
ian HIV-infected women appears to remain stable over time.
We found a standardized incidence ratio (SIR) of 0.91 (95% CI:
0.47-1.74), similar to that found by Polesel et al. for the period
from 1997 to 2004.3
In our study, patients with breast cancer were relatively
young, with a median age of 42 years (range 33-62 years),
which is similar to the age found in the study by de Andrade
et al., but is signiﬁcantly lower than the median age of breast
cancer in Italy, where the incidence rate increases with age,
reaching its highest levels at ages 65-69 years.
The majority of the women in our study did not have an
AIDS-deﬁning disease, and the median CD4+cell count at
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resentation of breast cancer (424 cells/mm3 with a range
rom 60 to 2,158 cells/mm3) demonstrated mild immunosup-
ression.
In contrast with the Brazilian study, where in two cases
urgery could not be performed due to serious clinical condi-
ions, in our case study all female patients underwent surgical
reatment and, moreover, full doses of systemic anti-cancer
herapies could be used, and the presence of HIV infection
id not inﬂuence the toxicity of chemotherapy. These factors
ould explain why our patients had a better survival out-
ome: ﬁve of the nine Brazilian patients died with a median
urvival of 12 months, while only two of our nine female
atients died, 32 and 49 months after breast cancer diagnosis,
espectively.
We also found a male breast cancer: to date, only two
ases have been reported in young HIV-infected men.4,5 Male
reast cancer is also very uncommon in HIV-uninfected
eople: worldwide, it accounts for almost 1% of all breast
alignancies, with an annual incidence in Europe that
as been estimated not to exceed 1 out of 100,000. More-
ver, while the incidence of female breast cancer is rising,
he incidence of male breast cancer remains almost stable
orldwide.
The review of breast diseases encountered in our HIV-
nfected population indicates that both men and women
iving with HIV infection and modest immunosuppression,
ncluding those treated with HAART, may present with neo-
lastic breast condition: breast cancer merits concern and
lose scrutiny also in the clinical picture of HIV infection.
The close monitoring we apply for HIV infection and
reatment represents an opportunity to institute recommen-
ations to prevent cancer: we have to increase awareness
f breast cancer in HIV-infected patients, also in men, and
o encourage all HIV-positive women to participate in breast
ancer screening. We have to also consider earlier mammog-
aphy exam than in the general population, as these patients
ight be subject to a risk of developing breast cancer earlier
n life.2;16(4):396–397 397
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